Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in Am J Gastroenterol

Retrieve available abstracts of 29 articles:
HTML format
Text format



Single Articles


    November 2018
  1. TORRES HA, Economides MP, Angelidakis G, Hosry J, et al
    Sofosbuvir-Based Therapy in Hepatitis C Virus-infected Cancer Patients: A Prospective Observational Study.
    Am J Gastroenterol. 2018 Nov 8. pii: 10.1038/s41395-018-0383.
    PubMed     Text format     Abstract available


    October 2018
  2. YEE HS, Burton MJ, Belperio PS, Morgan TR, et al
    The Veterans Affairs Hepatitis C Treatment Considerations.
    Am J Gastroenterol. 2018 Oct 12. pii: 10.1038/s41395-018-0231.
    PubMed     Text format    


    July 2018
  3. REDMAN JS, Sterling RK
    Treating HCV in a Captive Audience: Eradication Efforts in the Prison Microenvironment.
    Am J Gastroenterol. 2018 Jul 24. pii: 10.1038/s41395-018-0201.
    PubMed     Text format     Abstract available


  4. YOUNOSSI ZM
    Disparities in Access to Direct Acting Antiviral Regimens for Hepatitis C Virus (HCV): The Impact of Race and Insurance Status.
    Am J Gastroenterol. 2018 Jul 18. pii: 10.1038/s41395-018-0200.
    PubMed     Text format     Abstract available


    June 2018
  5. CUADRADO A, Llerena S, Cobo C, Pallas JR, et al
    Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
    Am J Gastroenterol. 2018 Jun 27. pii: 10.1038/s41395-018-0157.
    PubMed     Text format     Abstract available


  6. KRAWCZYK M, Gaweda B, Kosnik A, Rejowski S, et al
    Successful DAA-Based Treatment of Hcv-Related Fibrosing Cholestatic Hepatitis After Liver Transplantation Due to a Fulminant Liver Failure.
    Am J Gastroenterol. 2018 Jun 21. pii: 10.1038/s41395-018-0078.
    PubMed     Text format    


    April 2018
  7. ZAMOR PJ, Vierling J, Ghalib R, Luketic V, et al
    Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
    Am J Gastroenterol. 2018 Apr 26. pii: 10.1038/s41395-018-0053.
    PubMed     Text format     Abstract available


  8. PERRELLA A, Rinaldi L, Galeota-Lanza A, Izzi A, et al
    DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist.
    Am J Gastroenterol. 2018 Apr 24. pii: 10.1038/s41395-018-0062.
    PubMed     Text format    


    March 2018
  9. WONG RJ, Jain MK, Therapondos G, Shiffman ML, et al
    Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
    Am J Gastroenterol. 2018 Mar 9. pii: 10.1038/s41395-018-0033.
    PubMed     Text format     Abstract available


    December 2017
  10. BUNCHORNTAVAKUL C, Reddy KR
    HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary.
    Am J Gastroenterol. 2017 Dec 5. pii: ajg2017435. doi: 10.1038/ajg.2017.
    PubMed     Text format    


  11. NGUYEN MH, Trinh H, Do S, Nguyen T, et al
    Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naive or Experienced Patients.
    Am J Gastroenterol. 2017;112:1824-1831.
    PubMed     Text format     Abstract available


    November 2017
  12. KWO PY, Shiffman ML, Bernstein DE
    The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.
    Am J Gastroenterol. 2017 Nov 14. doi: 10.1038/ajg.2017.
    PubMed     Text format    


  13. SOLLIMA S, Milazzo L, Antinori S, Galli M, et al
    Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication.
    Am J Gastroenterol. 2017;112:1753-1754.
    PubMed     Text format    


  14. LIU X, Shen JJ, Lee JL, Yoo JW, et al
    Cost-Effective but Unaffordable and Unequal Hepatitis C Treatment in the US.
    Am J Gastroenterol. 2017;112:1749.
    PubMed     Text format    


  15. FUKUI N, Golabi P, Otgonsuren M, Mishra A, et al
    Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States.
    Am J Gastroenterol. 2017;112:1700-1708.
    PubMed     Text format     Abstract available


    October 2017
  16. WU T, Kwok RM, Tran TT
    Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.
    Am J Gastroenterol. 2017 Oct 31. doi: 10.1038/ajg.2017.
    PubMed     Text format     Abstract available


  17. KECK C, Shetty A, Mischen B, Willner I, et al
    Hepatic Splenosis Masquerading as Hepatocellular Carcinoma in a Chronic Hepatitis C Patient.
    Am J Gastroenterol. 2017;112:1493.
    PubMed     Text format    


    September 2017
  18. KOFF RS
    Editorial: Direct Antiviral Agents Eliminate the Age Barrier to Treatment of Chronic Hepatitis C.
    Am J Gastroenterol. 2017;112:1410-1411.
    PubMed     Text format     Abstract available


  19. LENS S, Fernandez I, Rodriguez-Tajes S, Hontangas V, et al
    Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
    Am J Gastroenterol. 2017;112:1400-1409.
    PubMed     Text format     Abstract available


    August 2017
  20. MARTIN P, Fabrizi F
    Editorial: Benefit of Direct-Acting Antiviral Therapy For Cryoglobulinemia due to Hepatitis C Infection.
    Am J Gastroenterol. 2017;112:1309-1310.
    PubMed     Text format     Abstract available


  21. EMERY JS, Kuczynski M, La D, Almarzooqi S, et al
    Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Am J Gastroenterol. 2017;112:1298-1308.
    PubMed     Text format     Abstract available


    April 2017
  22. LEE MH, Hsiao TI, Subramaniam SR, Le AK, et al
    HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.
    Am J Gastroenterol. 2017 Apr 25. doi: 10.1038/ajg.2017.
    PubMed     Text format     Abstract available


  23. OOKA K, Connolly JJ, Lim JK
    Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
    Am J Gastroenterol. 2017 Apr 4. doi: 10.1038/ajg.2017.
    PubMed     Text format    


    February 2017
  24. TAKYAR V, Kleiner DE, Koh C
    A Wolf in Sheep's Clothing in the Era of Non-Invasive Staging: Non-Hodgkin's Lymphoma Masquerading as Serologic HCV Cirrhosis.
    Am J Gastroenterol. 2017;112:398-399.
    PubMed     Text format    


  25. YANG JD, Mohamed HA, Cvinar JL, Gores GJ, et al
    Corrigendum: Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
    Am J Gastroenterol. 2017;112:402.
    PubMed     Text format    


    December 2016
  26. PILLAI AA, Anania FA, Pearlman BL
    Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
    Am J Gastroenterol. 2016;111:1854-1856.
    PubMed     Text format    


    August 2016
  27. TROJAN J, Sarrazin C
    Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Whishful thinking or Possible?
    Am J Gastroenterol. 2016;111:1208-9.
    PubMed     Text format    


    July 2016
  28. DI COSTANZO GG, Marino Marsilia G, Tortora R, Di Costanzo G, et al
    Hepatocellular Carcinoma With Peliosis-Like Change-Mimicking Hemangioma: A LI-RADS Exception.
    Am J Gastroenterol. 2016;111:1038-40.
    PubMed     Text format    


    March 2016
  29. SHI Y, Xia F, Li QJ, Li JH, et al
    Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study.
    Am J Gastroenterol. 2016 Mar 15. doi: 10.1038/ajg.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: